Sensitization of (colon) cancer cells to death receptor related therapies

References

• Viktorsson K, Lewensohn R, Zhivotovsky B. Apoptotic pathways and therapy resistance in human malignancies. Adv Cancer Res 2005; 94:143 - 96; http://dx.doi.org/10.1016/S0065-230X(05)94004-9; PMID: 16096001
   PubMed Web of Science ®Google Scholar
• Weitz J, Koch M, Debus J, Höhler T, Galle PR, Büchler MW. Colorectal cancer. Lancet 2005; 365:153 - 65; http://dx.doi.org/10.1016/S0140-6736(05)17706-X; PMID: 15639298
   PubMed Web of Science ®Google Scholar
• Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417:949 - 54; http://dx.doi.org/10.1038/nature00766; PMID: 12068308
   PubMed Web of Science ®Google Scholar
• Pratilas CA, Solit DB. Targeting the mitogen-activated protein kinase pathway: physiological feedback and drug response. Clin Cancer Res 2010; 16:3329 - 34; http://dx.doi.org/10.1158/1078-0432.CCR-09-3064; PMID: 20472680
   PubMed Web of Science ®Google Scholar
• Workman P, Clarke PA, Raynaud FI, van Montfort RL. Drugging the PI3 kinome: from chemical tools to drugs in the clinic. Cancer Res 2010; 70:2146 - 57; http://dx.doi.org/10.1158/0008-5472.CAN-09-4355; PMID: 20179189
   PubMed Web of Science ®Google Scholar
• Neckers L, Workman P. Hsp90 molecular chaperone inhibitors: are we there yet?. Clin Cancer Res 2012; 18:64 - 76; http://dx.doi.org/10.1158/1078-0432.CCR-11-1000; PMID: 22215907
   PubMed Web of Science ®Google Scholar
• Hernando E, Sarmentero-Estrada J, Koppie T, Belda-Iniesta C, Ramírez de Molina V, Cejas P, et al. A critical role for choline kinase-alpha in the aggressiveness of bladder carcinomas. Oncogene 2009; 28:2425 - 35; http://dx.doi.org/10.1038/onc.2009.91; PMID: 19448670
   PubMed Web of Science ®Google Scholar
• Ramírez de Molina A, Gallego-Ortega D, Sarmentero J, Bañez-Coronel M, Martín-Cantalejo Y, Lacal JC. Choline kinase is a novel oncogene that potentiates RhoA-induced carcinogenesis. Cancer Res 2005; 65:5647 - 53; http://dx.doi.org/10.1158/0008-5472.CAN-04-4416; PMID: 15994937
   PubMed Web of Science ®Google Scholar
• Cammareri P, Scopelliti A, Todaro M, Eterno V, Francescangeli F, Moyer MP, et al. Aurora-a is essential for the tumorigenic capacity and chemoresistance of colorectal cancer stem cells. Cancer Res 2010; 70:4655 - 65; http://dx.doi.org/10.1158/0008-5472.CAN-09-3953; PMID: 20460511
   PubMed Web of Science ®Google Scholar
• Ashkenazi A, Dixit VM. Death receptors: signaling and modulation. Science 1998; 281:1305 - 8; http://dx.doi.org/10.1126/science.281.5381.1305; PMID: 9721089
   PubMed Web of Science ®Google Scholar
• Grosse-Wilde A, Voloshanenko O, Bailey SL, Longton GM, Schaefer U, Csernok AI, et al. TRAIL-R deficiency in mice enhances lymph node metastasis without affecting primary tumor development. J Clin Invest 2008; 118:100 - 10; http://dx.doi.org/10.1172/JCI33061; PMID: 18079967
   PubMed Web of Science ®Google Scholar
• Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M, et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 1999; 5:157 - 63; http://dx.doi.org/10.1038/5517; PMID: 9930862
   PubMed Web of Science ®Google Scholar
• Wang S. The promise of cancer therapeutics targeting the TNF-related apoptosis-inducing ligand and TRAIL receptor pathway. Oncogene 2008; 27:6207 - 15; http://dx.doi.org/10.1038/onc.2008.298; PMID: 18931688
   PubMed Web of Science ®Google Scholar
• Wu XX, Kakehi Y. Enhancement of lexatumumab-induced apoptosis in human solid cancer cells by Cisplatin in caspase-dependent manner. Clin Cancer Res 2009; 15:2039 - 47; http://dx.doi.org/10.1158/1078-0432.CCR-08-2667; PMID: 19276256
   PubMed Web of Science ®Google Scholar
• Koschny R, Holland H, Sykora J, Haas TL, Sprick MR, Ganten TM, et al. Bortezomib sensitizes primary human astrocytoma cells of WHO grades I to IV for tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis. Clin Cancer Res 2007; 13:3403 - 12; http://dx.doi.org/10.1158/1078-0432.CCR-07-0251; PMID: 17545549
   PubMed Web of Science ®Google Scholar
• Oikonomou E, Kothonidis K, Taoufik E, Probert E, Zografos G, Nasioulas G, et al. Newly established tumourigenic primary human colon cancer cell lines are sensitive to TRAIL-induced apoptosis in vitro and in vivo. Br J Cancer 2007; 97:73 - 84; http://dx.doi.org/10.1038/sj.bjc.6603835; PMID: 17551494
   PubMed Web of Science ®Google Scholar
• Drosopoulos K, Pintzas A. Multifaceted targeting in cancer: the recent cell death players meet the usual oncogene suspects. Expert Opin Ther Targets 2007; 11:641 - 59; http://dx.doi.org/10.1517/14728222.11.5.641; PMID: 17465723
   PubMed Web of Science ®Google Scholar
• Grandemange S, Herzig S, Martinou JC. Mitochondrial dynamics and cancer. Semin Cancer Biol 2009; 19:50 - 6; http://dx.doi.org/10.1016/j.semcancer.2008.12.001; PMID: 19138741
   PubMed Web of Science ®Google Scholar
• Amm HM, Oliver PG, Lee CH, Li Y, Buchsbaum DJ. Combined modality therapy with TRAIL or agonistic death receptor antibodies. Cancer Biol Ther 2011; 11:431 - 49; http://dx.doi.org/10.4161/cbt.11.5.14671; PMID: 21263219
   PubMed Web of Science ®Google Scholar
• Wang Y, Engels IH, Knee DA, Nasoff M, Deveraux QL, Quon KC. Synthetic lethal targeting of MYC by activation of the DR5 death receptor pathway. Cancer Cell 2004; 5:501 - 12; http://dx.doi.org/10.1016/S1535-6108(04)00113-8; PMID: 15144957
   PubMed Web of Science ®Google Scholar
• Nesterov A, Nikrad M, Johnson T, Kraft AS. Oncogenic Ras sensitizes normal human cells to tumor necrosis factor-alpha-related apoptosis-inducing ligand-induced apoptosis. Cancer Res 2004; 64:3922 - 7; http://dx.doi.org/10.1158/0008-5472.CAN-03-2219; PMID: 15173003
   PubMed Web of Science ®Google Scholar
• Drosopoulos KG, Roberts ML, Cermak L, Sasazuki T, Shirasawa S, Andera L, et al. Transformation by oncogenic RAS sensitizes human colon cells to TRAIL-induced apoptosis by up-regulating death receptor 4 and death receptor 5 through a MEK-dependent pathway. J Biol Chem 2005; 280:22856 - 67; http://dx.doi.org/10.1074/jbc.M412483200; PMID: 15757891
   PubMed Web of Science ®Google Scholar
• Janssen KP, Alberici P, Fsihi H, Gaspar C, Breukel C, Franken P, et al. APC and oncogenic KRAS are synergistic in enhancing Wnt signaling in intestinal tumor formation and progression. Gastroenterology 2006; 131:1096 - 109; http://dx.doi.org/10.1053/j.gastro.2006.08.011; PMID: 17030180
   PubMed Web of Science ®Google Scholar
• Céspedes MV, Espina C, García-Cabezas MA, Trias M, Boluda A, Gómez del Pulgar MT, et al. Orthotopic microinjection of human colon cancer cells in nude mice induces tumor foci in all clinically relevant metastatic sites. Am J Pathol 2007; 170:1077 - 85; http://dx.doi.org/10.2353/ajpath.2007.060773; PMID: 17322390
   PubMed Web of Science ®Google Scholar
• Al-Saffar NM, Jackson LE, Raynaud FI, Clarke PA, Ramírez de Molina A, Lacal JC, et al. The phosphoinositide 3-kinase inhibitor PI-103 downregulates choline kinase alpha leading to phosphocholine and total choline decrease detected by magnetic resonance spectroscopy. Cancer Res 2010; 70:5507 - 17; http://dx.doi.org/10.1158/0008-5472.CAN-09-4476; PMID: 20551061
   PubMed Web of Science ®Google Scholar
• Eccles SA, Massey A, Raynaud FI, Sharp SY, Box G, Valenti M, et al. NVP-AUY922: a novel heat shock protein 90 inhibitor active against xenograft tumor growth, angiogenesis, and metastasis. Cancer Res 2008; 68:2850 - 60; http://dx.doi.org/10.1158/0008-5472.CAN-07-5256; PMID: 18413753
   PubMed Web of Science ®Google Scholar
• Gaspar N, Sharp SY, Pacey S, Jones C, Walton M, Vassal G, et al. Acquired resistance to 17-allylamino-17-demethoxygeldanamycin (17-AAG, tanespimycin) in glioblastoma cells. Cancer Res 2009; 69:1966 - 75; http://dx.doi.org/10.1158/0008-5472.CAN-08-3131; PMID: 19244114
   PubMed Web of Science ®Google Scholar
• Gaspar N, Sharp SY, Eccles SA, Gowan S, Popov S, Jones C, et al. Mechanistic evaluation of the novel HSP90 inhibitor NVP-AUY922 in adult and pediatric glioblastoma. Mol Cancer Ther 2010; 9:1219 - 33; http://dx.doi.org/10.1158/1535-7163.MCT-09-0683; PMID: 20457619
   PubMed Web of Science ®Google Scholar
• Chan F, Sun C, Perumal M, Nguyen QD, Bavetsias V, McDonald E, et al. Mechanism of action of the Aurora kinase inhibitor CCT129202 and in vivo quantification of biological activity. Mol Cancer Ther 2007; 6:3147 - 57; http://dx.doi.org/10.1158/1535-7163.MCT-07-2156; PMID: 18089709
   PubMed Web of Science ®Google Scholar
• Psahoulia FH, Moumtzi S, Roberts ML, Sasazuki T, Shirasawa S, Pintzas A. Quercetin mediates preferential degradation of oncogenic Ras and causes autophagy in Ha-RAS-transformed human colon cells. Carcinogenesis 2007; 28:1021 - 31; http://dx.doi.org/10.1093/carcin/bgl232; PMID: 17148506
   PubMed Web of Science ®Google Scholar
• Psahoulia FH, Drosopoulos KG, Doubravska L, Andera L, Pintzas A. Quercetin enhances TRAIL-mediated apoptosis in colon cancer cells by inducing the accumulation of death receptors in lipid rafts. Mol Cancer Ther 2007; 6:2591 - 9; http://dx.doi.org/10.1158/1535-7163.MCT-07-0001; PMID: 17876056
   PubMed Web of Science ®Google Scholar
• Oikonomou E, Koc M, Sourkova V, Andera L, Pintzas A. Selective BRAFV600E inhibitor PLX4720, requires TRAIL assistance to overcome oncogenic PIK3CA resistance. PLoS One 2011; 6:e21632; http://dx.doi.org/10.1371/journal.pone.0021632; PMID: 21738740
   PubMed Web of Science ®Google Scholar
• Rodríguez-González A, Ramírez de Molina A, Fernández F, Ramos MA, del Carmen Núñez M, Campos J, et al. Inhibition of choline kinase as a specific cytotoxic strategy in oncogene-transformed cells. Oncogene 2003; 22:8803 - 12; http://dx.doi.org/10.1038/sj.onc.1207062; PMID: 14654777
   PubMed Web of Science ®Google Scholar
• Rodríguez-González A, Ramírez de Molina A, Fernández F, Lacal JC. Choline kinase inhibition induces the increase in ceramides resulting in a highly specific and selective cytotoxic antitumoral strategy as a potential mechanism of action. Oncogene 2004; 23:8247 - 59; http://dx.doi.org/10.1038/sj.onc.1208045; PMID: 15378008
   PubMed Web of Science ®Google Scholar
• Bañez-Coronel M, Ramírez de Molina A, Rodríguez-González A, Sarmentero J, Ramos MA, García-Cabezas MA, et al. Choline kinase alpha depletion selectively kills tumoral cells. Curr Cancer Drug Targets 2008; 8:709 - 19; http://dx.doi.org/10.2174/156800908786733432; PMID: 19075594
   PubMed Web of Science ®Google Scholar
• Quintás-Cardama A, Cortes J. Homoharringtonine for the treatment of chronic myelogenous leukemia. Expert Opin Pharmacother 2008; 9:1029 - 37; http://dx.doi.org/10.1517/14656566.9.6.1029; PMID: 18377344
   PubMed Web of Science ®Google Scholar
• Vaculova A, Kaminskyy V, Jalalvand E, Surova O, Zhivotovsky B. Doxorubicin and etoposide sensitize small cell lung carcinoma cells expressing caspase-8 to TRAIL. Mol Cancer 2010; 9:87; http://dx.doi.org/10.1186/1476-4598-9-87; PMID: 20416058
   PubMed Web of Science ®Google Scholar
• Kaminskyy VO, Surova OV, Vaculova A, Zhivotovsky B. Combined inhibition of DNA methyltransferase and histone deacetylase restores caspase-8 expression and sensitizes SCLC cells to TRAIL. Carcinogenesis 2011; 32:1450 - 8; http://dx.doi.org/10.1093/carcin/bgr135; PMID: 21771726
   PubMed Web of Science ®Google Scholar
• Símová S, Klíma M, Cermak L, Sourková V, Andera L. Arf and Rho GAP adapter protein ARAP1 participates in the mobilization of TRAIL-R1/DR4 to the plasma membrane. Apoptosis 2008; 13:423 - 36; http://dx.doi.org/10.1007/s10495-007-0171-8; PMID: 18165900
   PubMed Web of Science ®Google Scholar
• Oikonomou E, Kosmidou V, Katseli A, Kothonidis K, Mourtzoukou D, Kontogeorgos G, et al. TRAIL Receptor Upregulation Correlates to KRAS/ BRAF Mutations in Human Colon Cancer Tumors and Respective Normal Tissue. Int J Cancer 2009; 125:2127 - 35; http://dx.doi.org/10.1002/ijc.24613; PMID: 19637313
   PubMed Web of Science ®Google Scholar
• Ramírez de Molina A, Sarmentero-Estrada J, Belda-Iniesta C, Tarón M, Ramírez de Molina V, Cejas P, et al. Expression of choline kinase alpha to predict outcome in patients with early-stage non-small-cell lung cancer: a retrospective study. Lancet Oncol 2007; 8:889 - 97; http://dx.doi.org/10.1016/S1470-2045(07)70279-6; PMID: 17851129
   PubMed Web of Science ®Google Scholar
• Sayan AE, Sayan BS, Gogvadze V, Dinsdale D, Nyman U, Hansen TM, et al. P73 and caspase-cleaved p73 fragments localize to mitochondria and augment TRAIL-induced apoptosis. Oncogene 2008; 27:4363 - 72; http://dx.doi.org/10.1038/onc.2008.64; PMID: 18362891
   PubMed Web of Science ®Google Scholar
• Briassouli P, Chan F, Savage K, Reis-Filho JS, Linardopoulos S. Aurora-A regulation of nuclear factor-kappaB signaling by phosphorylation of IkappaBalpha. Cancer Res 2007; 67:1689 - 95; http://dx.doi.org/10.1158/0008-5472.CAN-06-2272; PMID: 17308110
   PubMed Web of Science ®Google Scholar
• Lucken-Ardjomande S, Montessuit S, Martinou JC. Contributions to Bax insertion and oligomerization of lipids of the mitochondrial outer membrane. Cell Death Differ 2008; 15:929 - 37; http://dx.doi.org/10.1038/cdd.2008.9; PMID: 18259190
   PubMed Web of Science ®Google Scholar
• Lucken-Ardjomande S, Montessuit S, Martinou JC. Bax activation and stress-induced apoptosis delayed by the accumulation of cholesterol in mitochondrial membranes. Cell Death Differ 2008; 15:484 - 93; http://dx.doi.org/10.1038/sj.cdd.4402280; PMID: 18084240
   PubMed Web of Science ®Google Scholar
• Montessuit S, Somasekharan SP, Terrones O, Lucken-Ardjomande S, Herzig S, Schwarzenbacher R, et al. Membrane remodeling induced by the dynamin-related protein Drp1 stimulates Bax oligomerization. Cell 2010; 142:889 - 901; http://dx.doi.org/10.1016/j.cell.2010.08.017; PMID: 20850011
   PubMed Web of Science ®Google Scholar
• Olsson M, Vakifahmetoglu H, Abruzzo PM, Högstrand K, Grandien A, Zhivotovsky B. DISC-mediated activation of caspase-2 in DNA damage-induced apoptosis. Oncogene 2009; 28:1949 - 59; http://dx.doi.org/10.1038/onc.2009.36; PMID: 19347032
   PubMed Web of Science ®Google Scholar
• Powers MV, Clarke PA, Workman P. Dual targeting of HSC70 and HSP72 inhibits HSP90 function and induces tumor-specific apoptosis. Cancer Cell 2008; 14:250 - 62; http://dx.doi.org/10.1016/j.ccr.2008.08.002; PMID: 18772114
   PubMed Web of Science ®Google Scholar
• Vaughan CK, Mollapour M, Smith JR, Truman A, Hu B, Good VM, et al. Hsp90-dependent activation of protein kinases is regulated by chaperone-targeted dephosphorylation of Cdc37. Mol Cell 2008; 31:886 - 95; http://dx.doi.org/10.1016/j.molcel.2008.07.021; PMID: 18922470
   PubMed Web of Science ®Google Scholar
• Walczak H, Miller RE, Ariail K, Gliniak B, Griffith TS, Kubin M, et al. Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat Med 1999; 5:157 - 63; http://dx.doi.org/10.1038/5517; PMID: 9930862
   PubMed Web of Science ®Google Scholar
• Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK, et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 1995; 3:673 - 82; http://dx.doi.org/10.1016/1074-7613(95)90057-8; PMID: 8777713
   PubMed Web of Science ®Google Scholar
• de Jong S, Timmer T, Heijenbrok FJ, de Vries EG. Death receptor ligands, in particular TRAIL, to overcome drug resistance. Cancer Metastasis Rev 2001; 20:51 - 6; http://dx.doi.org/10.1023/A:1013112624971; PMID: 11831647
   PubMed Web of Science ®Google Scholar
• Gura T. How TRAIL kills cancer cells, but not normal cells. Science 1997; 277:768; http://dx.doi.org/10.1126/science.277.5327.768; PMID: 9273698
   PubMed Web of Science ®Google Scholar
• Voelkel-Johnson C, Hannun YA, El-Zawahry A. Resistance to TRAIL is associated with defects in ceramide signaling that can be overcome by exogenous C6-ceramide without requiring down-regulation of cellular FLICE inhibitory protein. Mol Cancer Ther 2005; 4:1320 - 7; http://dx.doi.org/10.1158/1535-7163.MCT-05-0086; PMID: 16170023
   PubMed Web of Science ®Google Scholar
• White-Gilbertson S, Mullen T, Senkal C, Lu P, Ogretmen B, Obeid L, et al. Ceramide synthase 6 modulates TRAIL sensitivity and nuclear translocation of active caspase-3 in colon cancer cells. Oncogene 2009; 28:1132 - 41; http://dx.doi.org/10.1038/onc.2008.468; PMID: 19137010
   PubMed Web of Science ®Google Scholar
• Rodríguez-González A, Ramirez de Molina A, Fernández F, Lacal JC. Choline kinase inhibition induces the increase in ceramides resulting in a highly specific and selective cytotoxic antitumoral strategy as a potential mechanism of action. Oncogene 2004; 23:8247 - 59; http://dx.doi.org/10.1038/sj.onc.1208045; PMID: 15378008
   PubMed Web of Science ®Google Scholar
• Zhivotovsky B, Orrenius S. Clinical perspectives of cell death: where we are and where to go.. Apoptosis 2009; 14:333 - 5; http://dx.doi.org/10.1007/s10495-009-0326-x; PMID: 19238546
   PubMed Web of Science ®Google Scholar
• Workman P, Collins I. Probing the probes: fitness factors for small molecule tools. Chem Biol 2010; 17:561 - 77; http://dx.doi.org/10.1016/j.chembiol.2010.05.013; PMID: 20609406
   PubMed Web of Science ®Google Scholar
• Workman P, de Bono J. Targeted therapeutics for cancer treatment: major progress towards personalised molecular medicine. Curr Opin Pharmacol 2008; 8:359 - 62; http://dx.doi.org/10.1016/j.coph.2008.07.007; PMID: 18678282
   PubMed Web of Science ®Google Scholar
• Yap TA, Sandhu SK, Workman P, de Bono JS. Envisioning the future of early anticancer drug development. Nat Rev Cancer 2010; 10:514 - 23; http://dx.doi.org/10.1038/nrc2870; PMID: 20535131
   PubMed Web of Science ®Google Scholar